CJC-1295 (no DAC) 5mg
CJC-1295 (no DAC) – a modified GHRH analog resistant to DPP-4, studied for pulsatile growth hormone release. Price and batch analysis.
45.00 EUR · In stock
This product is intended solely for scientific and research use, as well as for use as a reference standard in HPLC analysis, and is not an approved medicinal product. It is not intended for the diagnosis, treatment or prevention of disease in humans or animals. It has not been approved by the FDA, the EMA or any national regulator. The information on this page is provided for scientific information purposes only and does not constitute medical advice, a recommendation for use, or any claim of clinical efficacy or safety.
CJC-1295 – what the peptide is
CJC-1295 is a modified analog of growth hormone-releasing hormone, built on the GHRH (1-29) sequence. The compound carries four amino acid substitutions, the purpose of which is to protect it from the rapid degradation that the natural molecule undergoes.
The main target of this degradation is the enzyme dipeptidyl peptidase-4, which cleaves the initial amino acids of GHRH within minutes. The substitutions in CJC-1295 slow down this process and extend the molecule's presence in circulation.
The no-DAC variant does not carry the additional binding group that, in the other form, allows attachment to albumin. This is also the reason the two forms are considered separately in the literature – they differ significantly in duration of action.
Mechanism of action
The molecule binds to the GHRH receptor in the anterior pituitary gland and triggers release of stored growth hormone. The mechanism is identical to that of natural GHRH, with the difference lying in the time profile.
Since regulation remains subject to somatostatin, release retains a pulsatile character. In the literature this is described as a difference compared to the continuous presence observed with direct administration of growth hormone.
The no-DAC form has a significantly shorter duration of action than the DAC form, which explains why the two are studied as separate compounds rather than interchangeable variants.
Research data and observations
Observations track concentrations of growth hormone and IGF-1 following administration. It is noted that the no-DAC form produces more pronounced but shorter-lived changes compared to the long-acting form.
A separate line of work examines combining a GHRH analog with a ghrelin receptor agonist. The two groups act through different receptors, and the discussion focuses on whether their effects are additive.
Individual variability in response is significant and is attributed to differences in pituitary reserve.
When interpreting published data, the difference between preclinical and clinical conditions should be taken into account. Results from cell cultures and animal models describe mechanism but do not allow quantitative conclusions for human conditions.
The dose ranges used in preclinical studies are often not directly translatable due to differences in metabolism between species. This limitation is consistently noted in review papers.
Example calculations
The calculations below are purely mathematical examples showing the relationship between the total amount of substance, the volume of solvent, and the resulting concentration. They do not represent a dosing recommendation, administration schedule, or instructions for use.
When dissolving 5 mg with 2 ml bacteriostatic water:
The resulting concentration is 2.5 mg/ml, with 0.40 ml containing 1 mg of substance.
Example values:
- 0.1 ml = 0.25 mg
- 0.2 ml = 0.5 mg
- 0.3 ml = 0.75 mg
- 0.4 ml = 1 mg
- 0.5 ml = 1.25 mg
Overview of scientific publications
The literature on modified GHRH analogs is more limited than that on the natural hormone. Some publications do not clearly distinguish between the two forms of CJC-1295, which complicates comparison.
Review papers recommend explicitly specifying the form studied when citing results.
Safety data from studies
Reported observations include reactions at the injection site and short-term manifestations related to vasodilation. A concentration-dependent relationship is noted.
Systematic data from long-term human studies have not been published in the available literature.
The general limitation for compounds in this category is the absence of long-term controlled studies in humans. The available information describes mechanism and short-term observations, not a safety profile for prolonged use.
The product is intended exclusively for research purposes. It is not a food, dietary supplement, or medicinal product and is not intended for the diagnosis, treatment, or prevention of disease.